ePrints

Low dose continuous infusion doxorubicin in children and young adults

Lookup NU author(s): Professor Andrew Pearson, Dr Jennifer Kernahan, Dr Helen Lucraft, Anne Thompson, Emeritus Professor Alan Craft

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Ten patients (age range 3.2-26.3 yrs) with relapsed or resistant malignancies received a total of 20 courses of low dose continuous infusion doxorubicin (3 mg/m2/day for 28 days) delivered by portable Graseby infusion pumps via central venous catheters. Each patient received a median dose of 144 mg/m2 (range 87-261). Four patients responded to treatment (1 complete response (CR) and 3 partial response (PR)) and performance status improved in seven patients. Overall toxicity was minimal: WHO Grade 4 anaemia in 2/18 courses, Grade 4 neutropenia in 1/18, Grade 3-4 thrombocytopenia in 3/18, nausea and vomiting of Grades 2 and 4 in 4/20 and 1/20 respectively, and mucositis of Grades 2 and 4 in 2/20 courses each. Cardiac toxicity was assessed using echocardiography, and fractional shortening remained within normal limits in all patients. Low dose continuous infusion doxorubicin is a feasible, well tolerated, ambulatory therapy in children and may be an effective way of delivering doxorubicin with less toxicity, thus enabling the development of more dose intensive regimens. (C) 1993 Wiley-Liss, Inc.

Publication metadata

Author(s): Kynaston, J. A., Pearson, A. D. J., Kernahan, J., Lucraft, H. H., Barstow, D., Thompson, A., Craft, A. W.

Publication type: Article

Publication status: Published

Journal: Medical and Pediatric Oncology

Year: 1993

Volume: 21

Issue: 7

Pages: 494-498

ISSN (print): 0098-1532

ISSN (electronic): 1545-5017

URL: http://dx.doi.org/10.1002/mpo.2950210707

DOI: 10.1002/mpo.2950210707

PubMed id: 8341217

Altmetrics

Share